原発性硬化性胆管炎市場：薬剤クラス別、投与経路別、流通チャネル別、地域別

原発性硬化性胆管炎の世界市場は、2025年には1億7,410万米ドルと推定され、2032年には2億9,860万米ドルに達すると予測され、2025～2032年にかけてCAGR8.0％で成長すると予測されます。

図.原発性硬化性胆管炎市場シェア（%）、2025年地域別

原発性硬化性胆管炎（PSC）は、肝内・肝外胆管の多巣性狭窄と線維化を特徴とする慢性進行性胆汁うっ滞性肝疾患です。70～80％の症例で炎症性腸疾患（通常は潰瘍性大腸炎）を伴います。PSCの正確な原因は不明であるが、遺伝的感受性と環境的誘因の複雑な相互作用から生じる自己免疫疾患であると考えられています。PSCの世界の有病率は、10万人当たり13～16人と推定されています。現在のところ、PSCの治療法はなく、症状の緩和と病気の進行を遅らせることが治療の中心です。原発性硬化性胆管炎の世界市場の成長は、診断率の上昇と医療支出の増加によってもたらされます。

市場力学

原発性硬化性胆管炎の世界市場成長は、疾患に対する認知度の向上、診断方法の進歩による診断率の上昇、PSCを発症しやすい高齢者の世界の増加といった要因によって牽引されます。しかし、PSCの治療として承認された薬剤がないことや、発症機序が複雑であることが市場成長の妨げになる可能性があります。新規治療開発のための継続的な研究開発や新興国市場における医療費の増加は、市場参入企業にとって大きな収益機会をもたらす可能性があります。

本調査の主要特徴

本レポートでは、世界の原発性硬化性胆管炎市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模と複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて説明しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の原発性硬化性胆管炎市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。

本調査の対象となる主要企業には、Intercept Pharmaceuticals、Dr. Falk Pharma GmbH、Acorda Therapeutics Inc.などが含まれます。

本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の原発性硬化性胆管炎市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。

利害関係者は、世界の原発性硬化性胆管炎市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の原発性硬化性胆管炎市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の原発性硬化性胆管炎市場、薬剤クラス別、2020～2032年、（100万米ドル）

• イントロダクション
• ウルソデオキシコール酸（UDCA）
• コルチコステロイド
• アザチオプリン
• メルカプトプリン
• ブデソニド
• オベチコール酸
• モノクローナル抗体
• その他

第6章 世界の原発性硬化性胆管炎市場、投与経路別、2020～2032年、（100万米ドル）

• イントロダクション
• 経口
• 非経口
• その他

第7章 世界の原発性硬化性胆管炎市場、流通チャネル別、2020～2032年、（100万米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の原発性硬化性胆管炎市場、地域別、2020～2032年、（100万米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Dr. Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

第10章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Primary Sclerosing Cholangitis Market is estimated to be valued at USD 174.1 Mn in 2025 and is expected to reach USD 298.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.

Figure. Primary Sclerosing Cholangitis Market Share (%), By Region 2025

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic liver disease characterized by multifocal strictures and fibrosis of the intrahepatic and extrahepatic bile ducts. It is associated with inflammatory bowel disease, usually ulcerative colitis, in 70-80% of cases. The exact cause of PSC remains unknown, but it is believed to be an autoimmune disease resulting from a complex interplay between genetic susceptibility and environmental triggers. The global prevalence of PSC is estimated to range between 13-16 cases per 100,000 individuals. Currently, there is no cure for PSC and treatment is focused on relieving symptoms and slowing disease progression. Global primary sclerosing cholangitis market growth is driven by increasing diagnosis rates and rising healthcare expenditure.

Market Dynamics:

Global primary sclerosing cholangitis market growthis driven by factors like rising awareness about the disease, increasing diagnosis rates attributed to advanced diagnostic modalities, and growing geriatric population worldwide who are more susceptible to develop PSC. However, lack of an approved drug for treating PSC and complexities associated with the disease pathogenesis can hamper the market growth. Ongoing R&D for developing novel therapeutics and increasing healthcare expenditures in emerging nations can present high-impact profitable opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global primary sclerosing cholangitis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global primary sclerosing cholangitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Intercept Pharmaceuticals, Dr. Falk Pharma GmbH, and Acorda Therapeutics Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market

Detailed Segmentation-

• By Drug Class
  • Ursodeoxycholic acid (UDCA)
  • Corticosteroids
  • Azathioprine
  • Mercaptopurine
  • Budesonide
  • Obeticholic acid
  • Monoclonal antibody
  • Others
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Acorda Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Primary Sclerosing Cholangitis Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Primary Sclerosing Cholangitis Market, By Drug Class, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ursodeoxycholic acid (UDCA)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Azathioprine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Mercaptopurine
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Budesonide
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Obeticholic acid
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Monoclonal antibody
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Primary Sclerosing Cholangitis Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Primary Sclerosing Cholangitis Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Primary Sclerosing Cholangitis Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Acorda Therapeutics, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • NGM Biopharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Intercept Pharmaceuticals, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Falk Pharma GmbH
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Allergan Plc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceutical Ltd.
  • Cymabay Therapeutics
  • Pliant Therapeutics
  • Immunic AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact